Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 561 - 570 of 742 studies

Unmasking concealed arrhythmia syndromes (RASE BRUGADA GEL)

Cutaneous Responses to Diphenylcyclopropenone to evaluate Immunomodulatory Therapeutics (CUREDIT)

CORRELATE-UK: COnsistency of Response with RimegEpant oral Lyophilisate in Acute Treatment of migrainE in the United Kingdom (CORRELATE-UK)

A prospective pilot cohort study to investigate the accuracy and utility of wearables in preoperative assessment in addition to cardiopulmonary exercise testing in predicting outcomes for patients who have undergone oesophagogastric cancer surgery.

Musculoskeletal

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44) (ENTR-601-44-201 (ELEVATE-44))

Cardiovascular

ICONIC-M: Improving CRT outcome with non-invasive cardiac mapping A multicentre randomised controlled study to assess patient response to CRT comparing ECGI map-guided left ventricular lead placement with empirical lead placement. (ICONIC-M)

A register for collecting and measuring outcomes of licensed Anti-Epileptic Drugs and Epilepsy treatments in patients with Epilepsy and Intellectual Disability and/or Pervasive Developmental Disorders (EP-ID Register)

Cancer and neoplasms

Master Protocol Title: A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib - ISA JZ01 Title: Long-Term Safety of Pirtobrutinib in Participants from Study LOXO-BTK-18001 with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non- Hodgkin Lymphoma (J2N-MC-JZNY (ISA: J2N-MC-JZ01))

Blood Cancer and neoplasms

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (KER-050-D301 (RENEW))

PROgnosiS Prediction after Enhanced or CriTical care (PROSPECT)